logo-loader
viewZynerba Pharmaceuticals

Zynerba wins new US patent for treatment of Autism Spectrum Disorder with CBD

The patent comes at an opportune times as enrollment speeds up in Zynerba’s open label Phase 2 BRIGHT study evaluating the safety, and potency of its Zygel CBD gel

Medical marijuana
Zynerba's principal line of business are cannabinoid (CBD) treatments delivered via the skin to treat neurological and psychiatric disorders

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) revealed Tuesday that the US Patent and Trademark Office granted the company a new patent for treating Autism Spectrum Disorder, characterized by challenges with social skills and speech, with cannabidiol (CBD).

The company said it received US Patent No 10,314,792, titled “Treatment of Autism Spectrum Disorder with Cannabidiol,” which includes claims linked to methods of treating Autism Spectrum Disorder by administering a therapeutically effective amount of synthetic CBD.

The new patent, which expires in 2038, is part of an expanding intellectual property portfolio covering the Devon, Pennsylvania-based company’s Zygel, a CBD gel.

Zygel was earlier referred to as ZYN002, a synthetic cannabidiol formulated as a permeation-enhanced gel for skin delivery.

READ: Zynerba Pharmaceuticals scores Fast Track FDA designation for Zygel CBD gel

The new patent arrives as enrollment speeds up in Zynerba’s open label Phase 2 BRIGHT study evaluating the safety, tolerability and potency of Zygel for treating children and adolescents with Autism Spectrum Disorder. The company expects to report top line data in the first half of 2020.

Zynerba already has a patent (No 10,213,390) for claims linked to methods of treating Fragile X Syndrome by administering an effective dose of synthetic or purified CBD.

The US Food and Drug Administration earlier granted fast track designation to Zygel to expedite the development of the drug to treat Fragile X syndrome in children and young adults suffering from this common form of inherited learning disability and attention deficit disorder.

Enrollment is progressing in a pivotal CONNECT-FX Trial of Zygel in Fragile X syndrome, the company said in a statement with “data expected in the second half of 2019.”

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

Quick facts: Zynerba Pharmaceuticals

Price: 5.71 USD

NASDAQ:ZYNE
Market: NASDAQ
Market Cap: $132.46 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zynerba Pharmaceuticals named herein, including the promotion by the Company of Zynerba Pharmaceuticals in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Zynerba Pharmaceuticals well-funded for its CBD clinical trials into 2021

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) CEO Armando Anido tells Proactive Investors the Pennsylvania-based biotech has $59.8 million to fund clinical trials for its cannabis-derived treatments 'beyond major milestones' into 2021. Zynerba is on track to report top-line results from tests...

on 03/12/2019

2 min read